Agenda

Return

C.100

To:	Board of Supervisors
From:	Anna Roth, Health Services Director
Date:	April 20, 2021

Contra

Costa

County

Subject:

Purchase Order with Becton Dickinson and Company

APPROVE	OTHER
RECOMMENDATION OF CNTY ADMINISTRATOR	RECOMMENDATION OF BOARD COMMITTEE

Action of Board On: 04/20/2021

APPROVED AS RECOMMENDED

OTHER

Clerks Notes:

VOTE OF SUPERVISORS

AYE:

John Gioia, District I Supervisor
Candace Andersen, District II Supervisor
Diane Burgis, District III Supervisor
Karen Mitchoff, District IV Supervisor
Federal D. Glover, District V Supervisor

Contact:	Jaspreet Benepal, 925-370-5101
cc:	Margaret Harris Marcy Wilhelm

I hereby certify that this is a true and correct copy of an action taken and entered on the minutes of the Board of Supervisors on the date shown.
ATTESTED: April 20, 2021
Monica Nino, County Administrator

BY:	, Deputy

RECOMMENDATION(S):

APPROVE and AUTHORIZE the Purchasing Agent to execute, on behalf of the Health Services Director, a Purchase Order with Becton Dickinson and Company, in an amount not to exceed $300,000 for reagents and supplies used by the microbiology unit at the clinical laboratory at the Contra Costa Regional Medical Center (CCRMC) and Contra Costa Health Centers, for the period from December 21, 2020 through December 20, 2027.

FISCAL IMPACT:

This purchase order will result in expenditures of up to $300,000 and will be funded 100% by Hospital Enterprise Fund I revenues.

BACKGROUND:

The CCRMC Clinical Laboratory uses blood culturing as a tool in diagnosing sepsis, which is the number one cause of death in patients with COVID-19. Rapid diagnosis of a bloodstream infection is the key in selecting the correct targeted antibiotic therapy to help the patient fight the infection. The rental of the BD BACTEC along with reagents and supplies that are needed to perform tests will help improve the recovery of positive blood cultures as well as improve the time to detection of those organisms.

CONSEQUENCE OF NEGATIVE ACTION:

If this purchase order is not approved, the CCRMC clinical laboratory will not be able to perform the specific patient testing that allows providers to correctly target the correct therapy to fight infections.